February 28, 2022 -- Real estate investment manager Capri EGM has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience.
Ology Bioservices, a wholly-owned subsidiary of Resilience, and the operator of the lab & research facility has recently been awarded a contract valued at $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT). Resilience also has a multi-year agreement to produce mRNA for Moderna’s COVID-19 vaccine, a strategic multi-year R&D alliance with Harvard University to develop complex medicines and a multi-product biomanufacturing development agreement with Takeda Pharmaceutical supporting their plasma-derived medicines portfolio. The Resilience Lab & Research build-to-suit is strategically located in North Florida’s Research and Life Science cluster. Capri EGM is an established real estate investment company specializing in corporate build-to-suit and sale leaseback financing and the acquisition of income-generating logistics, life science, and R&D corporate real estate in high-growth markets throughout the U.S. National Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. No financial details of the deal were disclosed.Copyright © 2022 scienceboard.net